Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
AAVE To Rally Higher? Key Pattern Signals Potential Upside Move

AAVE To Rally Higher? Key Pattern Signals Potential Upside Move

CoinsProbeCoinsProbe2025/07/17 16:15
By:Nilesh Hembade

Date: Thu, July 17, 2025 | 05:48 AM GMT

The cryptocurrency market has entered bullish territory, with Ethereum (ETH) leading the charge with its impressive 21% weekly gains, having crossed the $3,350 mark. This wave of bullishness is lifting major altcoins — and Aave (AAVE) is now flashing signs of joining the rally.

The DeFi token has jumped 7% over the past week, but what’s catching even more attention is the emergence of a technical setup on the chart — signaling a potential upside move.

AAVE To Rally Higher? Key Pattern Signals Potential Upside Move image 0 AAVE Daily Chart/Coinsprobe (Source: Tradingview)

ABC Zigzag Pattern in Play?

AAVE appears to be in the early stages of forming a classic ABC Zigzag corrective wave pattern — and if this plays out, the token may be gearing up for a powerful leg higher. The move from $114.16 to $317.68 marked Wave (A), showing a strong bullish impulse. This was followed by a healthy pullback to $213.25, completing Wave (B). Now, AAVE is climbing again, suggesting Wave (C) is underway — the final leg of the pattern, typically another impulsive upward move.

AAVE To Rally Higher? Key Pattern Signals Potential Upside Move image 1 AAVE Daily Chart/Coinsprobe (Source: Tradingview)

If this structure continues to unfold as expected, AAVE could be heading toward a target range between $416 and $542. These levels represent the 1.0x and 1.618x Fibonacci extensions of Wave A, often used to project the end of Wave C. From the current price around $322, this move could bring gains of nearly 29% to 68% — if the bullish sentiment continues.

What’s Next?

For the bullish outlook to remain intact, AAVE needs to hold above the $323.56 level, which closely aligns with the peak of Wave (A). Sustaining this level would likely confirm the structure and open the doors for further upside. However, if the price drops below $300, it could temporarily delay the rally or lead to some consolidation.

With momentum building and technical patterns aligning, AAVE could be preparing for a strong rally — but as always, traders should remain cautious and watch for confirmations.

1
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales